85% of Fertility Grant Applicants Lack Treatment Coverage, New Data from The Stork Foundation Reveals

The Stork Foundation received a record 1,076 applications for fertility-treatment grants in 2026; 85% of applicants lacked insurance coverage for the treatment pursued, and the average anticipated cost of their next treatment course was $19,149. The nonprofit launched its “$6 for 1 in 6” campaign, running through Giving Tuesday on December 1, 2026, to fund additional grants of up to $15,000.

Analysis

The signal is social need, not near-term listed-company earnings: a single nonprofit campaign is unlikely to change treatment volumes or pricing meaningfully. The investable second-order question is whether affordability pressure prompts employers to add fertility benefits or expands public-policy mandates. Either could support utilization for fertility-benefit administrators such as Progyny and fertility clinics, but any benefit accrues only if coverage translates into incremental treatment starts and durable economics—not merely broader eligibility or higher utilization costs.

Near term (days to December 1), there is no evident catalyst for public equities; the campaign’s fundraising outcome is not a reliable proxy for industry demand. Over 1–3 months, watch employer-benefit announcements and grant recipients’ treatment access, while recognizing that one foundation’s applicant pool is not representative of the addressable market. Over 6–18 months, state coverage rules, employer renewal decisions, and treatment affordability are the more consequential drivers. The contrarian read is that unmet need does not automatically mean investable growth: without payer coverage or improved household financing, demand may remain latent. A thesis of stronger commercial volumes is falsified if benefit adoption rises without corresponding treatment-start growth, or if clinic/benefit-provider disclosures show weaker utilization or economics.

Key Decisions for Investors

• No immediate trade: the campaign is a weak, non-commercial signal and does not establish a change in listed-company revenue or earnings.
• Put Progyny and fertility-care providers on watch for employer benefit renewals, covered-member growth, treatment starts, and disclosed unit economics; do not infer those outcomes from the nonprofit’s applications or fundraising alone.
• Treat expanded employer coverage or state mandates as the actionable catalyst. Reassess only when there is verifiable adoption and utilization evidence; absent that, avoid paying for a broad demand-expansion thesis.
• Falsification trigger: benefit availability increases but treatment starts or provider economics fail to improve over subsequent reporting periods.